Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)

Immobilized PD-L1 Protein, Mouse (HEK293, His, HY-P70632) can bind Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2). The EC₅₀ for this effect is 9.78 ng/mL.

Flow cytometric analysis of 1X10⁶ MC38 cells with Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) (HY-P99145, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rat IgG H&L (HY-P89199) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Rat IgG2a kappa (HY-P990679, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 28;16(1):8054. [Abstract]

Customer Validation
In vivo NIR-II fluorescence images, ratio plots and the corresponding ratio signal (F_{1060 nm}/F_{1525 nm}) values at the tumor site on day 10 after anti-PD-L1 antibody (Anti-Mouse PD-L1/B7-H1 Antibody, 100 μg in 100 μL PBS; i.p.; every three days for a total of three doses) treatment in tumor-bearing mice.

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 5;16(1):10880. [Abstract]

Customer Validation
NIR-IIb fluorescence ratiometric imaging and NIR-IIb fluorescence quantification/ratiometric analysis of different groups. In the immunotherapy group, the mice received intraperitoneal injection of anti-PD-L1 antibody (Anti-Mouse PD-L1/B7-H1 Antibody) on alternate days. On day 7, the mice received intravenous injection with Bi-HCy-ErNPs (n = 6).

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jan 28;23(1):48. [Abstract]

Customer Validation
Fluorescence microscopy observations of aPDL1-DTX/PFP@Lipid binding to Pan02 cells. Red fluorescence indicates NPs labeled with DiI (scale bar = 25 μm). The results showed that the binding of nanoparticles was reduced in the presence of free aPD-L1 antibody (Anti-Mouse PD-L1/B7-H1 Antibody).

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(15):e2412109. [Abstract]

Customer Validation
Tumor size, tumor growth curves, and tumor volume of C57BL/6 mice injected subcutaneously with U14 cells (n = 4). The results showed that anti-mouse PD-L1/B7-H1 antibody (αPD-L1, 3 mg/kg; i.p.; twice a week) monotherapy significantly slowed tumor growth, whereas combination therapy with FK866 (20 mg/kg; i.p.; twice a week) and αPD-L1 achieved the strongest tumor suppressive effect.

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) purchased from MedChemExpress. Usage Cited in: J Control Release. 2025 Sep 10:385:113998. [Abstract]

Customer Validation
Photographs of tumors from the same treatment groups and changes in tumor volume during treatment. antiPD-L1 antibody (Anti-Mouse PD-L1/B7-H1 Antibody, 100 μg/mouse; administered every two days for three doses).

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2025 Sep 30;9(1):319. [Abstract]

Customer Validation
The stable cell line was inoculated into immunocompetent BALB/c mice to generate subcutaneous xenografts, which were treated with either αPD‑L1 Ab (Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2), 100 μg; i.p.; every three days; HY-P99145) or IgG isotype control (Rat IgG2b kappa, Isotype Control (100 μg; i.p.; every three days)). Images of subcutaneous xenograft tumors harvested from euthanized mice in different groups.

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2025 Sep 30;9(1):319. [Abstract]

Customer Validation
The stable cell line was inoculated into immunocompetent BALB/c mice to generate subcutaneous xenografts, which were treated with either αPD‑L1 Ab (Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2), 100 μg; i.p.; every three days; HY-P99145) or IgG isotype control (Rat IgG2b kappa, Isotype Control (100 μg; i.p.; every three days)). Flow cytometric analysis of CD3⁺ cells within CD45⁺ cells and CD8⁺ cells within CD3⁺ T cells in the tumors.